IGF2 and cancer: Additionally, a comprehensive analysis using the tumor immune dysfunction and exclusion (TIDE) system was conducted on 4,028 tumor samples from 9 cancer types of TCGA database, indicating significantly higher IGF2 expression in the immune-excluded tumors (Supplemental Figure 1C).